Education
About Us
Working with TipRanks
Follow Us
Cencora, Inc. (DE:ABG)
NYSE:ABG
ABG Stock Chart & Stats
€301.70
€6.65(3.05%)
At close: 4:00 PM EST
€301.70
€6.65(3.05%)
Day’s Range― - ―
52-Week Range€228.40 - €325.25
Previous CloseN/A
Volume0.00
Average Volume (3M)19.00
Market Cap
€59.95B
Enterprise Value€76.31B
Total Cash (Recent Filing)€1.75B
Total Debt (Recent Filing)€7.92B
Price to Earnings (P/E)40.1
Beta-0.08
Next Earnings
May 06, 2026EPS Estimate
4.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.44
Shares Outstanding194,530,690
10 Day Avg. Volume2
30 Day Avg. Volume19
Financial Highlights & Ratios
PEG Ratio7.05
Price to Book (P/B)40.17
Price to Sales (P/S)0.19
P/FCF Ratio18.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€352.55Price Target Upside16.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyAcquisition of OneOncology is expected to add incremental adjusted operating income to the US Healthcare segment and shift the portfolio toward higher-growth oncology services, supporting accelerated earnings growth.
Guidance And OutlookManagement raised long-term targets for adjusted operating income and adjusted EPS to reflect contributions from OneOncology, indicating stronger medium-term profit potential.
Industry Fundamentals And ValuationStabilization in generic drug pricing and removal of major litigation and drug-pricing overhangs improves sector fundamentals and supports a higher valuation multiple for the distributor group.
Bears Say
Capital Allocation And BuybacksA pause in share repurchases ahead of the OneOncology transaction reduces buyback-driven support for the stock and increases reliance on successful deal execution to justify capital deployment.
Customer Concentration And Regulatory RiskDependence on a major client and prior regulatory uncertainty underline customer concentration and policy risks that could weigh on investor confidence if issues recur.
Segment Growth SlowdownA slowdown in year-over-year growth in the US Healthcare segment triggered share-price declines and highlights the risk of weaker near-term revenue momentum.
Cencora News
ABG FAQ
What was Cencora, Inc.’s price range in the past 12 months?
Cencora, Inc. lowest stock price was €228.40 and its highest was €325.25 in the past 12 months.
What is Cencora, Inc.’s market cap?
Cencora, Inc.’s market cap is €59.95B.
When is Cencora, Inc.’s upcoming earnings report date?
Cencora, Inc.’s upcoming earnings report date is May 06, 2026 which is in 81 days.
How were Cencora, Inc.’s earnings last quarter?
Cencora, Inc. released its earnings results on Feb 04, 2026. The company reported €3.438 earnings per share for the quarter, beating the consensus estimate of €3.412 by €0.026.
Is Cencora, Inc. overvalued?
According to Wall Street analysts Cencora, Inc.’s price is currently Undervalued.
Does Cencora, Inc. pay dividends?
Cencora, Inc. does not currently pay dividends.
What is Cencora, Inc.’s EPS estimate?
Cencora, Inc.’s EPS estimate is 4.11.
How many shares outstanding does Cencora, Inc. have?
Cencora, Inc. has 194,530,690 shares outstanding.
What happened to Cencora, Inc.’s price movement after its last earnings report?
Cencora, Inc. reported an EPS of €3.438 in its last earnings report, beating expectations of €3.412. Following the earnings report the stock price went down -7.756%.
Which hedge fund is a major shareholder of Cencora, Inc.?
Currently, no hedge funds are holding shares in DE:ABG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cencora Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€352.55 (16.85% Upside)
€352.55 (16.85% Upside)
Blogger Sentiment
Bullish
DE:ABG Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $6.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
49.35%
12-Months-Change
Fundamentals
Return on Equity
152.25%
Trailing 12-Months
Asset Growth
13.48%
Trailing 12-Months
Company Description
Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
ABG Company Deck
ABG Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong execution and clear growth momentum: revenue, gross profit, adjusted EPS and consolidated operating income all increased, leadership completed a strategic MSO acquisition (OneOncology), and management raised both revenue and operating income guidance for fiscal 2026. Key drivers included specialty growth (including GLP-1s), RCA outperformance, and MSO expansion. Near-term pressures were acknowledged — higher operating and interest expenses from acquisitions and financing, a seasonal negative free cash flow quarter, timing-related international operating income weakness, and customer off-boarding — but management framed many as transitory or expected to normalize over the year. Overall, positive operational trends and upgraded guidance outweigh the near-term challenges.View all DE:ABG earnings summariesABG Revenue Breakdown
90.55% U.S. Healthcare Solutions
9.45% International Healthcare Solutions
>-0.01% Intersegment eliminations
ABG Stock 12 Month Forecast
Average Price Target
€352.55
▲(16.85% Upside)
Technical Analysis
Options Prices
Currently, No data available
---